Richard Stanley Bedlack
Professor of Neurology
Overview
2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.
3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.
Selected Grants
COMBAT-ALS awarded by (Principal Investigator). 2020 to 2022
ALS Telemedicine awarded by (Principal Investigator). 2020 to 2021
The Duke ALS Association Certified Center awarded by (Principal Investigator). 2018 to 2021
A Pilot Trial of Triheptanoin for People with Amyotrophic Lateral Sclerosis (PALS) awarded by (Principal Investigator). 2018 to 2020
ALS Telemedicine awarded by (Principal Investigator). 2018 to 2020
Integrated Genomics in Clinical ALS (GTAC) awarded by Columbia University (Principal Investigator). 2016 to 2019
CYTO-5022 awarded by (Principal Investigator). 2017 to 2019
Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE) awarded by University of Miami (Principal Investigator). 2014 to 2019
Retigabine and or Ezogabine in ALS awarded by (Principal Investigator). 2015 to 2018
Neuraltus NP001 awarded by (Principal Investigator). 2016 to 2018
Pages
Mitsumoto, Hiroshi, et al. “Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis.” Amyotroph Lateral Scler Frontotemporal Degener, Apr. 2020, pp. 1–10. Pubmed, doi:10.1080/21678421.2020.1746810. Full Text
Fournier, Christina N., et al. “Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).” Jama Neurol, vol. 77, no. 4, Apr. 2020, pp. 480–88. Pubmed, doi:10.1001/jamaneurol.2019.4490. Full Text
Urbi, Berzenn, et al. “Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.” Bmj Open, vol. 9, no. 11, Nov. 2019, p. e029449. Pubmed, doi:10.1136/bmjopen-2019-029449. Full Text
Bedlack, Rick. “ALSUntangled 48: Perampanel (Fycompa).” Amyotroph Lateral Scler Frontotemporal Degener, vol. 20, no. 5–6, Aug. 2019, pp. 453–56. Pubmed, doi:10.1080/21678421.2019.1573850. Full Text
Bedlack, R. S., et al. “Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial.” Amyotroph Lateral Scler Frontotemporal Degener, vol. 20, no. 3–4, May 2019, pp. 285–93. Pubmed, doi:10.1080/21678421.2018.1556698. Full Text
Bedlack, Richard. “ALSUntangled No. 47: RT001.” Amyotroph Lateral Scler Frontotemporal Degener, vol. 20, no. 3–4, May 2019, pp. 294–97. Pubmed, doi:10.1080/21678421.2018.1549531. Full Text
ALSUntangled Group, Richard, and Richard Bedlack. “ALSUntangled 46: penicillin G/hydrocortisone.” Amyotroph Lateral Scler Frontotemporal Degener, vol. 20, no. 1–2, Feb. 2019, pp. 126–31. Pubmed, doi:10.1080/21678421.2018.1512704. Full Text
Statland, Jeffrey M., et al. “Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.” Muscle Nerve, vol. 59, no. 2, Feb. 2019, pp. 201–07. Pubmed, doi:10.1002/mus.26335. Full Text
Bedlack, R., et al. “ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors.” Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Jan. 2019. Scopus, doi:10.1080/21678421.2019.1690519. Full Text
Woolley, Susan, et al. “Corrigendum to "Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients".” Behav Neurol, vol. 2019, 2019, p. 6704740. Pubmed, doi:10.1155/2019/6704740. Full Text
Pages
Bedlack, Richard S., et al. “Scrutinizing enrollment in ALS clinical trials: Room for improvement?” Neurology, vol. 70, no. 11, LIPPINCOTT WILLIAMS & WILKINS, 2008, pp. A344–A344.
Bedlack, R. S., and S. Torres. “Multifocal motor neuropathy with upper motor neuron signs.” Muscle & Nerve, vol. 34, no. 4, JOHN WILEY & SONS INC, 2006, pp. 514–514.
Bedlack, R. S., et al. “Apolipoprotein E genotype is a risk factor for diabetic neuropathy.” Annals of Neurology, vol. 52, no. 6, WILEY-LISS, 2002, pp. 866–866.
Gross, E., et al. “Fluorescent imaging of membrane potential components.” Analytical Use of Fluorescent Probes in Oncology, edited by E. Kohen and J. G. Hirschberg, vol. 286, PLENUM PRESS DIV PLENUM PUBLISHING CORP, 1996, pp. 249–56.
BEDLACK, R. S., et al. “ENDOGENOUS ELECTRIC-FIELDS WITHIN THE NEURONAL PLASMALEMMA - NONUNIFORMITIES SUGGESTING DIFFERENTIAL VOLTAGE-DEPENDENCE.” Biophysical Journal, vol. 66, no. 2, BIOPHYSICAL SOCIETY, 1994, pp. A387–A387.
GROSS, E., et al. “DUAL-WAVELENGTH RATIOMETRIC FLUORESCENCE MEASUREMENT OF THE MEMBRANE DIPOLE POTENTIAL.” Biophysical Journal, vol. 66, no. 2, BIOPHYSICAL SOCIETY, 1994, pp. A387–A387.
BEDLACK, R. S., et al. “ELECTRIC FIELD-BIASED N1E-115 GROWTH CONE FILOPODIAL PROTRUSIONS ARE INHIBITED BY VERAPAMIL.” Biophysical Journal, vol. 64, no. 2, BIOPHYSICAL SOCIETY, 1993, pp. A101–A101.